Clinical Trials Logo

Non-melanoma Skin Cancer clinical trials

View clinical trials related to Non-melanoma Skin Cancer.

Filter by:

NCT ID: NCT06428721 Recruiting - Aging Clinical Trials

The Preventive Role of Fractionated Laser Resurfacing Against Actinic Neoplasia in an At-Risk Geriatric Population

Start date: March 20, 2024
Phase: N/A
Study type: Interventional

The purpose of this study is to determine if the Fractionated Laser Resurfacing (FLR) procedure can protect one forearm/wrist from precancerous actinic keratosis (AKs) as well as prevent skin cancer in older subjects with active AKs. This study builds on a similar study ongoing at the Dayton Veterans Administration dermatology clinic. This study is also testing if a photograph of the skin can be used to predict where the AKs and an skin cancers will form.

NCT ID: NCT06384053 Not yet recruiting - Clinical trials for Basal Cell Carcinoma

Skin Cancer and Hyperthermia and Radiotherapy

SAHARA
Start date: July 1, 2024
Phase: N/A
Study type: Interventional

The SAHARA trial assesses wether combining ultrahypofractionated accelerated radiotherapy (RT) with hyperthermia is as effective as standard hypofractionated high-dose radiation in treating non-melanoma skin cancer (NMSC).

NCT ID: NCT06227416 Active, not recruiting - Clinical trials for Squamous Cell Carcinoma

Skin Tumor Biomarkers by Mass Spectrometry Imaging

Start date: June 15, 2020
Phase: N/A
Study type: Interventional

The purpose of the study is to investigate the ability of mass spectrometry imaging to locate aggregates of basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) ex-vivo, and to distinguish areas containing these carcinomas from normal skin. It is suggested that non-melanoma skin cancer (NMSC) cells show a different profile of endogenous lipids than healthe skin tissue which can be used as identifying biomarkers. If that hypothesis is correct it will be possible in the future to develop real-time tissue diagnosis and treatment of NMSC using mass spectrometry guided surgery. Method between 60 and 100 patients with BCCs, SCCs, and actinic keratoses (AK) will be recruited. For patients referred for Mohs surgical procedure at the Department of Dermatology, Bispebjerg Hospital, to treat BCCs or SCCs, three skin sections (5-10 um thick) of the tissue that is already removed will be use in our study. One section will be HE stained so we know exactly where the regions of interest are. Two sections will be used for MS analysis (MSI spectrum and REIMS spectrum). When patients are referred for a procedure to have treated several actinic keratoses (grade 1, 2 or 3) at Department of Dermatology, Bispebjerg Hospital we will take an extra punch biopsy (2-4 mm) depending on the size of the lesion. The biopsy is embedded and sectioned. We will use 3 skin sections (5-10 um thick) we will again use one section for HE staining and two for MS analysis. Multivariate statistical analysis will be performed on all mass spectra using Matlab or similar program. Linear discriminant analysis will be used to identify spectral differences between pre-malignant, cancer and normal tissue. Classification performance will be recorded with a leave-one- patient- out cross- validation scheme.

NCT ID: NCT05955924 Recruiting - Clinical trials for Carcinoma, Squamous Cell

Nicotinamide Chemoprevention for Keratinocyte Carcinoma in Solid Organ Transplant Recipients - Pivotal Trial

SPRINTR
Start date: August 28, 2023
Phase: Phase 3
Study type: Interventional

As patients live longer after receiving an organ transplant, there is a need to reduce the long-term side effects of the drugs used to prevent organ rejection. In particular, long-term use of these drugs increases the risk of skin cancer. Skin cancer is now a leading cause of illness and disfigurement after kidney, liver, heart, and lung transplantation. Given the increased risk and burden of skin cancer in transplant recipients, prevention is critical. Nicotinamide is a form of Vitamin B3 that has been shown to protect against skin cancer in the general population. However, it is unclear whether nicotinamide is effective among immune-suppressed transplant recipients. Investigators will conduct a clinical trial involving multiple transplant centres in Canada to evaluate whether oral nicotinamide (500 mg twice daily) is effective and safe for preventing skin cancer. Investigators will recruit 396 high-risk adult kidney, liver, heart, and lung transplant patients who have previously had at least one skin cancer. Patients will receive nicotinamide or sham tablets for up to 4 years. The results will inform efforts to improve the long-term health of transplant recipients.

NCT ID: NCT05932511 Recruiting - Clinical trials for Squamous Cell Carcinoma

Topical Ascorbic Acid for Treatment of Squamous Cell Skin Cancer

Start date: June 12, 2023
Phase: Early Phase 1
Study type: Interventional

Randomized comparative trial of a 30% solution of ascorbic acid in 95% dimethylsulfoxide applied topically twice a day for 8 weeks vs 5% imiquimod cream in the treatment of biopsy proven squamous cell carcinomas of the skin in otherwise healthy adult patients. Outcome measure was biopsy proven resolution of the carcinoma.

NCT ID: NCT05878288 Recruiting - Neoplasms Clinical Trials

Deep sequencIng in Cutaneous Squamous CEll caRciNomas

DISCERN
Start date: May 26, 2023
Phase: Phase 2
Study type: Interventional

To comprehensively describe the molecular profile of the tumour ecosystem of cutaneous squamous cell carcinoma (CSCC) patients treated with neoadjuvant immunotherapy using single-cell sequencing and bulk genomic profiling.

NCT ID: NCT05842421 Completed - Clinical trials for Non-melanoma Skin Cancer

Imaging Methods for the Diagnosis of Non-melanoma Skin Cancer and Its Precursors

Start date: April 21, 2021
Phase: N/A
Study type: Interventional

Prospective, unicentric study that examines if imaging devices like total body photography, dermoscopy, optical coherence tomography and in vivo reflectance confocal microscopy as an addition to clinical examination lead to a benefit for patients in the diagnosis of non-melanoma skin cancer and their precursors

NCT ID: NCT05602792 Recruiting - Breast Cancer Clinical Trials

A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumors

Start date: April 21, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

A Phase I/IIa Study of the Safety and Tolerability of T3011 Administered via Intratumoral Injection in Patients with Advanced Solid Tumors

NCT ID: NCT05550766 Not yet recruiting - Clinical trials for Non-melanoma Skin Cancer

Prognostic Value of RXR-α in Cutaneous Squamous and Basal Cell Carcinoma

Start date: December 2022
Phase:
Study type: Observational

Vitamin D has a crucial role in cancer control and prevention.vitamin D receptor (VDR) and its heterodimer Retinoid X receptor (RXR) are equally important in the cell. This ligand (vitamin D) and receptors (VDR-RXR) complex together triggers downstream DNA damage response in the cell. Retinoid receptors are a superfamily of nuclear receptors. The preferred receptor that attaches to VDR is RXR, with its subunits α, β and γ. RXR α is more frequent in the skin than other tissues, while β occurs in internal organs and γ is frequently related to neural disorders. the investigator hopes to assess prognosis of SCC & BCC by using RXR-α biomarker & attempts to use it in the treatment.

NCT ID: NCT05429866 Recruiting - Breast Cancer Clinical Trials

Immunological Variables Associated to ICI Toxicity in Cancer Patients

Start date: September 1, 2022
Phase: Phase 2
Study type: Interventional

This is a monocentric, prospective, pilot study that will enrol 435 subjects with solid tumours that are treated with immune checkpoint inhibitor(s) (ICI) alone or in combination with chemotherapy or targeted therapy. For enrolled subjects, clinical and laboratory evaluations will be performed and reported at different time points: - Early (4-6 weeks after treatment start) - Midtime (8-11 weeks after treatment start) - Late (13-18 weeks after treatment start) - At the occurrence of immune-related adverse events (irAEs), clinical and laboratory evaluation will be performed at two principal time points: - For the 1st time of any grade 1 or 2 irAE if the subject developed it. - For the 1st time of any grade 3 or 4 irAE if the subject developed it.